AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
The HemOnc Pulse
Drs. Dahiya, Spiegel Discuss CAR-T Secondary Malignancies Risk
Feb 8, 2024
Discussion on the risks of secondary malignancies from CAR-T therapy, challenges of attributing lymphomas to CAR-T, exploration of insertional mutagenesis impact, concerns about myeloid neoplasms, and unique aspects of filter cell CAR-T therapy.
40:56
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- CAR-T therapy can lead to secondary myeloid neoplasms, emphasizing the need for risk evaluation and patient counseling.
- Variations in CAR constructs may impact rates of secondary malignancies, highlighting the importance of understanding their implications.
Deep dives
Discussion on Secondary Malignancies from CAR-T Cellular Therapy
The podcast episode delves into the topic of secondary malignancies arising from CAR-T cellular therapy. Researchers discuss their findings related to T-cell lymphomas and therapy-related myeloid malignancies post-CAR-T treatment. Dr. Spiegel and Dr. Dahia provide insights into the associations between CAR-T therapy and secondary malignancies. Their studies reported cases of secondary myeloid neoplasms in patients treated with CAR-T, shedding light on the complexities of the risks involved.
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode